Ppgl Pediatric Surgical Approach

---
name: ppgl-pediatric-surgical-approach
description: Determines surgical approach for PPGL in children considering tumor size, suspected pathogenic gene variants, and hereditary tumor syndromes. Chooses between laparotomy and endoscopic surgery based on child's size and genetic risk; incorporates family history and genetic testing results in decision-making, with triggers such as 'Child diagnosed with PPGL requiring surgery,' 'Need to select surgical approach for pediatric PPGL,' and 'Evaluating surgical options in child with genetic syndrome.'
---

# Pediatric PPGL Surgical Approach Considerations

## STEP 1 — Gather Information
Collect child's age, weight, and body surface area; tumor diameter via contrast-enhanced CT or MRI; family history of PPGL or hereditary tumor syndromes (VHL, RET, SDHx, NF1, MEN2); results of germline genetic testing if available; biochemical confirmation with fractionated metanephrines or plasma-free metanephrines; presence of syndromic features.

## STEP 2 — Rule In / Rule Out
If tumor diameter ≤ 3 cm AND no high‑risk pathogenic variant (VHL, RET, SDHB) AND no known hereditary tumor syndrome → proceed to endoscopic evaluation; otherwise → proceed to laparotomy evaluation.

## STEP 3 — Classify or Stratify
Endoscopic pathway: classify as laparoscopic adrenalectomy (LA) for children ≥5 years or tumor accessible via standard ports; consider robot‑assisted laparoscopic adrenalectomy (RAA) if available and child size permits.  
Laparotomy pathway: classify as open transabdominal adrenalectomy (OA) for tumors >3 cm or suspected multifocal/bilateral disease; consider posterior retroperitoneoscopic approach only if expertise exists and tumor is small and lateral.

## STEP 4 — Decide
Endoscopic: schedule LA or RAA after preoperative α‑blockade; Laparotomy: schedule OA with prepared blood products and experienced team; arrange genetic counseling and postoperative surveillance per hereditary syndrome.

## Clinical Guardrails / Mimics / Pitfalls
Avoid laparoscopy in tumors >3 cm due to bleeding risk; ensure α‑blockade ≥7‑14 days preoperatively; do not rely on endoscopic approach in VHL, RET, or SDHB carriers without multidisciplinary review; false‑negative genetic testing does not exclude hereditary syndrome; monitor for intraoperative hemodynamic instability even in small tumors.

## Concrete Clinical Example
A 6‑year‑old girl with episodic hypertension, abdominal tumor 2.4 cm on MRI, family history of VHL, germline VHL pathogenic variant confirmed. Despite tumor ≤3 cm, hereditary syndrome triggers laparotomy; she undergoes open transabdominal adrenalectomy with uneventful recovery.

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, I-10-3, doi:10.1507/endocrj.EJ25-0165